Sat, 28 Nov 2020

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Exicure, Inc. (NYSE American:XCUR), is developing nucleic acid-based therapeutics to treat rare, severe genetic diseases and cancer. XCUR will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.

The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based in Chicago, IL.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.investorsummitgroup.com

Or, contact Brittney Blocker at brittney@investorsummitgroup.com

SOURCE: Exicure, Inc.



View source version on accesswire.com:
https://www.accesswire.com/615958/Exicure-Inc-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th

More Oklahoma City News

Access More

Sign up for Oklahoma City News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!